July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Changes of OCTA Findings after Treatment in Polypoidal Choroidal Vasculopathy
Author Affiliations & Notes
  • Seung-Young Yu
    Ophthalmology, Kyung Hee University, Seoul, Korea (the Democratic People's Republic of)
  • Jae Min Kim
    Ophthalmology, Kyung Hee University, Seoul, Korea (the Democratic People's Republic of)
  • Sung Rae Noh
    Ophthalmology, Kyung Hee University, Seoul, Korea (the Democratic People's Republic of)
  • Kiyoung Kim
    Ophthalmology, Kyung Hee University, Seoul, Korea (the Democratic People's Republic of)
  • Kunho Bae
    Ophthalmology, Kyung Hee University, Seoul, Korea (the Democratic People's Republic of)
  • Eung-Suk Kim
    Ophthalmology, Kyung Hee University, Seoul, Korea (the Democratic People's Republic of)
  • Footnotes
    Commercial Relationships   Seung-Young Yu, None; Jae Min Kim, None; Sung Rae Noh, None; Kiyoung Kim, None; Kunho Bae, None; Eung-Suk Kim, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3222. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Seung-Young Yu, Jae Min Kim, Sung Rae Noh, Kiyoung Kim, Kunho Bae, Eung-Suk Kim; Changes of OCTA Findings after Treatment in Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3222.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The purpose of this study was to evaluate the change of the lesion on OCTA following treatment in patients with polypoidal choroidal vasculopathy (PCV).

Methods : Retrospective medical record was reviewed in 16 eyes with treatment-naïve PCV, seen at Kyunghee University Hospital between May 2016 and January 2017. All patients underwent ophthalmic examination such as ICGA, OCT, OCTA and fundus photography. Patients diagnosed with PCV were treated with monotherapy (Intravitreal ranibizumab or aflibercept injection) or combination therapy (Photodynamic therapy and intravitreal ranibizumab injection). PDT was performed only in the polyp region, not containing BVN. The ratio of polyp regression and recurrence were analyzed.

Results : Sixteen eyes of 16 patients (11 male, 5 female) were included in the study. Average age was 68.43±9.07 years. The number of each treatment were 11 eyes for monotherapy and 5 eyes for combination therapy. At baseline, the polypoidal lesions detected in ICGA were found in 11 eyes (69%) by OCTA, of which hypoflow halo form was in 4 eyes (25%) and hyperflow form was in 7 eyes (44%). The BVN were detected in 7 eyes (44%) by ICGA and in 12 eyes (75%) by OCTA. Among the 7 eyes of hyperflow that cleary showed the appearance of polyp on OCTA, the decrease of size and disappearance of polypoidal lesion in 6 months after therapy was detected respectively in 3 eyes (43%) and in 3 eyes (43%). The decrease of size of BVN in 6 months after therapy was detected in 8 eyes (67%). The recurrence of polypoidal lesion and BVN in 6 months after therapy was detected each in 1 eyes (14%) and in 4 eyes (33%). Of the 4 eyes with recurrence of BVN, 3 eyes were recurred within 2 months after 3 consecutive monotherapy and 1 eye was recurred at 4 months after combination therapy and additional 2 consecutive intravitreal injection.

Conclusions : The OCTA is a noninvasive and good imaging tool for detecting vascular changes in PCV. Branching vascular networks showed more clearly on OCTA than on ICGA. On the other hand, polypoidal lesions were detected in variable patterns (hyperflow or hypoflow halo) on OCTA and showed more clearly on ICGA than on OCTA. Although the OCTA is difficult to use as primary tool to diagnose PCV, it can be a very effective method for observing post-treatment progression in patients with PCV.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×